Cargando…

Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels

There are several hurdles to overcome before implementing pharmacogenomics (PGx) in precision medicine. One of the hurdles is unawareness of PGx by clinicians due to insufficient pharmacogenomic information on drug labels. Therefore, it might be important to implement PGx that reflects pharmacogenom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Deok Yong, Lee, Soyoung, Ban, Mu Seong, Jang, In-Jin, Lee, SeungHwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781807/ https://www.ncbi.nlm.nih.gov/pubmed/33425802 http://dx.doi.org/10.12793/tcp.2020.28.e18

Ejemplares similares

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
por: Abdullah-Koolmees, Heshu, et al.
Publicado: (2021)

Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB
por: Alshabeeb, Mohammad A., et al.
Publicado: (2022)

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
por: Manson, Lisanne E. N., et al.
Publicado: (2020)

Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
por: Westergaard, Niels, et al.
Publicado: (2020)

Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
por: Caudle, Kelly E., et al.
Publicado: (2014)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022)

Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements
por: Shekhani, Rawan, et al.
Publicado: (2019)

Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021)

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC(®)) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics
por: Blazy, Christopher, et al.
Publicado: (2022)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
por: Stanek, Eric J., et al.
Publicado: (2013)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
por: Caudle, Kelly E., et al.
Publicado: (2017)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view
por: Varnai, Reka, et al.
Publicado: (2019)

Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
por: Kim, Hyun Chul, et al.
Publicado: (2022)

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs
por: Agúndez, José A. G., et al.
Publicado: (2014)

Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects
por: Yang, Eunsol, et al.
Publicado: (2019)

Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects
por: Jung, Jihyun, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Pharmacogenomics of cardiovascular drugs
por: Adithan, C
Publicado: (2014)

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available
por: Samwald, Matthias, et al.
Publicado: (2016)

Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations
por: Li, Dan, et al.
Publicado: (2020)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
por: Yang, Eunsol, et al.
Publicado: (2021)

Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform
por: Kim, Byungwook, et al.
Publicado: (2021)

Deciphering next-generation pharmacogenomics: an information technology perspective
por: Potamias, George, et al.
Publicado: (2014)

Pharmacogenomics: The Genomics of Drug Response
por: March, Ruth
Publicado: (2000)

Pharmacogenomics of adverse drug reactions
por: Daly, Ann K
Publicado: (2013)

Pharmacogenomics of GPCR Drug Targets
por: Hauser, Alexander S., et al.
Publicado: (2018)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

An EMR-Based Approach to Determine Frequency, Prescribing Pattern, and Characteristics of Patients Receiving Drugs with Pharmacogenomic Guidelines
por: MacKinnon, George E., et al.
Publicado: (2023)

Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
por: Choi, YoonJung, et al.
Publicado: (2016)

Pharmacogenomics: Activating Cancer Drug Discovery
por: Mead, M. Nathaniel
Publicado: (2004)

Pharmacogenomics: The Right Drug to the Right Person
por: T P, Aneesh, et al.
Publicado: (2009)

Role of pharmacogenomics in drug discovery and development
por: Surendiran, A., et al.
Publicado: (2008)

Pharmacogenomics in Personalized Medicine and Drug Metabolism
por: Chang, Wei-Chiao
Publicado: (2014)

Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014)

Editorial: Pharmacogenomics of Adverse Drug Reactions
por: Siddiqui, Moneeza K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3qe2e520kptdm8690sbo96guu4